Skip to content
MSK Department of Medicine· @MSK_DeptOfMed · X·· 2026-04-21Score60
Body

Kicking off today's poster session at #AACR26: Dr. Brian Chernak will share phase I results on ruxolitinib + the CDK4/6 inhibitor abemaciclib in previously treated #myelofibrosis.
@MSKCancerCenter

@AACR

@BrianChernak

9 a.m.–12 p.m. PDT

https://
bit.ly/4dRLPK1

Heat 9 · 5 likes · 0 replies · 4 reposts

Conference abstracts
CT262matched by 药名 abemaciclib
Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Giuliano Borges, Rinat Yerushalmi, Marina N. Sharifi, Wassim McHayleh, Thaddeus Beck, Neelima Vidula, Erika Hamilton, Kristine J. Rinn, Joyce O’Shaughnessy, Giuseppe Curigliano, Javier Cortés, Paula Muñoz Romero, Giulia Tonini, Alessandro Paoli, Monica Binaschi, Li Cheng, Jennifer A. Crozier, Tomer Wasserman, Virginia Kaklamani

Read the abstract →

Source: MSK Department of Medicine · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org